Aucubin inhibits epithelial-mesenchymal transition and angiogenesis in colorectal cancer via the HDAC6/PI3K/Akt signaling pathway
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-07 · 399 (10) · 14945-14964
DOI: 10.1007/s00210-026-05332-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 18.04.2026. Verfasst von Jinsong Su und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Colorectal Neoplasms, Neovascularization, Pathologic, Iridoid Glucosides. Die Arbeit nennt 63 Literaturangaben.
Abstract (Originalsprache)
Colorectal cancer (CRC) represents a prevalent malignancy worldwide, with its high incidence and mortality rates necessitating novel therapeutic strategies. Aucubin (AU), a natural compound, has demonstrated diverse biological activities, yet its role and mechanisms in CRC remain incompletely understood. The effects of AU on the malignant biological behaviors of CRC were evaluated by CCK-8 assay, colony formation, Transwell, tube formation, wound healing, and flow cytometry experiments. ELISA quantification of angiogenic markers (MMP-2, MMP-9, VEGFA), immunofluorescence detection of epithelial-mesenchymal transition (EMT) markers (E-cadherin/N-cadherin) and key pathway protein (HDAC6), alongside Western blot assessment of EMT-related proteins, angiogenesis factors, and HDAC6/PI3K/Akt pathway components (HDAC6, p-PI3K/PI3K, p-AKT/AKT). Mechanistic investigations employed HDAC6-overexpressing and knockdown cell models. In vivo, HCT116 xenograft models were established for tumor volume/weight measurements, immunohistochemistry, HE staining, TUNEL assays, and Western blot validation. In vitro, AU significantly suppressed HCT116/SW620 cell proliferation, migration, and invasion while promoting apoptosis. AU reversed EMT phenotypes via E-cadherin upregulation and N-cadherin/Vimentin/Snail downregulation, concurrently inhibiting MMP-2/9 activity. AU impaired HUVEC tube formation and reduced VEGFA/FGF2/PDGF-BB expression. Mechanistically, AU inhibited HDAC6 expression and PI3K/Akt phosphorylation. HDAC6 overexpression partially rescued AU's effects, whereas HDAC6 knockdown potentiated them. In vivo results corroborated these findings, showing suppressed tumor growth, reduced Ki-67 expression, improved histopathology, enhanced apoptosis, and modulated expression of EMT/angiogenesis/HDAC6/PI3K/Akt pathway proteins. This study demonstrates that AU exerts antitumor effects by suppressing EMT and angiogenesis through HDAC6/PI3K/Akt pathway inhibition. Clinical trial number: not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
- Key Laboratory of Ageing and Cancer Biology of Zhejiang Province, Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Hangzhou Normal University, 2318 Yu Hang Tang Road, Hangzhou, 311121, Zhej…
Zitieren
APA
Su, J., Wan, T., Tian, S., & Dai, B. (2026). Aucubin inhibits epithelial-mesenchymal transition and angiogenesis in colorectal cancer via the HDAC6/PI3K/Akt signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(10), 14945-14964. https://doi.org/10.1007/s00210-026-05332-7
Vancouver
Su J, Wan T, Tian S, Dai B. Aucubin inhibits epithelial-mesenchymal transition and angiogenesis in colorectal cancer via the HDAC6/PI3K/Akt signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(10):14945-14964. doi:10.1007/s00210-026-05332-7
BibTeX
@article{Su2026,
author = {Su, Jinsong and Wan, Tianqi and Tian, Shengnan and Dai, Baiyun},
title = {Aucubin inhibits epithelial-mesenchymal transition and angiogenesis in colorectal cancer via the HDAC6/PI3K/Akt signaling pathway},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {10},
pages = {14945--14964},
doi = {10.1007/s00210-026-05332-7}
}
EUVIMED